Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]